telesisbio.com (TBIO) - Total Stockholders' Equity
Telesis Bio, Inc. (TBIO) develops DNA synthesis instruments, ensuring high scalability through the recurring sale of high-cost reagents. Software lock-in and patent protection create a powerful moat that prevents the expansion of new players. The current metric is -0.02. This price chart illustrates the trading dynamics, accounting for strict FDA control and administrative support in science.
Summary analytical data breakdowns for Telesis Bio (TBIO)
Book value capitalization reflects the value of Telesis Bio, Inc. (TBIO) net assets under US GAAP standards minus all debt obligations, allowing investors to determine the fundamental value of the business without market noise. Analyzing the company's book value capitalization is critical, as resource deficits and the complexities of commercializing synthetic biology systems increase the risk of overpayment when a significant gap exists between market and real value.